Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1001 plus pembrolizumab and chemotherapy for stage IV NSCLC
NL-OMON61182Phase 2Not yet recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BDB001 in non-small cell lung cancer (NSCLC), sponsored by Eikon Therapeutics. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61182.